Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

aflibercept ophthalmic

aflibercept ophthalmic
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Ahzantive SOLUTION, INTRAOCULAR 40 mg/mL    
Enzeevu SOLUTION, INTRAOCULAR 40 mg/mL    
Eylea SOLUTION, INTRAOCULAR 40 mg/mL    
Opuviz SOLUTION, INTRAOCULAR 40 mg/mL    
Pavblu SOLUTION, INTRAOCULAR 40 mg/mL    
Yesafili SOLUTION, INTRAOCULAR 40 mg/mL    
Comments:

Eylea and all biosimilars reviewed by the Committee are classified as therapeutically equivalent to the reference product and non-formulary, not stocked.

Currently, HH is using bevacizumab (Avastin) drawn up in small doses for exudative age-related macular degeneration.

 

Reviewed: 22 Oct 2013 (Eylea),  July 2025 (Ahzantive, Enzeevu, Pavblu, Yesafili, Opuviz)    

Aflibercept (EYLEA) Biosimilar Comparison Chart.pdf

Formulary Evaluation on Ahzantive.pdf

Formulary Evaluation on Enzeevu.pdf

Aflibercept-ayyh (PAVBLU) Spotlight.pdf

Yesafili Comparison.pdf

Opuviz Comparison.pdf

Last updated: Jul. 31, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved